New Lung Cancer Drug Cuts Death Risk by 34% in Trial

A groundbreaking cancer treatment just showed remarkable results that exceeded doctors' expectations in treating one of the deadliest forms of lung cancer.

The drug ivonescimab reduced the risk of death by 34% compared to standard treatment for patients with squamous non-small cell lung cancer.